Abstract 472P
Background
Esophageal squamous cell carcinoma (ESCC) has a poor prognosis in Asian regions and the immunotherapy targeting PD-1 is on the stage of clinical trials. This study aims to investigate the prognostic effect of PD-1 expression in intratumoral and stromal tumor-infiltrating lymphocytes (TILs) on relapse and overall survival of ESCC patients.
Methods
A retrospective cohort study was conducted with recruiting 142 ESCC patients who received surgical treatment. Intratumoral and stromal PD-1 expression was tested by immunohistochemistry (IHC).
Results
The median follow-up time was 22 months and 21.1% patients were lost of follow-up. Cell counts and expression rate of intratumoral PD1+ TILs did not show any association with disease-free survival (DFS) and overall survival (OS). Expression rate of stromal PD1+ TILs did not have a significant relationship with DFS. The patients with expression rate of stromal PD1+ TILs >20% had the median OS being 19 months and the patients with expression rate ≤20% did not achieved median OS (p = 0.034). The adjusted HR of higher expression rate was 1.49 (95%CI 0.82, 2.60, p = 0.189) for OS. ESCC patients with ≤18 stromal PD1+ TILs/HPF had the median DFS being 10 months however the patients with >18 cells/HPF had the median DFS being 48 months (p = 0.037). The adjusted HR of > 18 stromal PD1+ TILs/HPF on DFS was 0.59 (95%CI 0.35, 1.01, p = 0.055). With reference to the patients of lower expression rate/higher cell counts of stromal PD1+ TILs, patients with lower expression rate/lower cell counts, higher expression rate/higher cell counts, and higher expression rate/lower cell counts, had the adjusted HR for DFS increased to 3.73, 3.36 and 3.99 (p for trend being 0.030) and the adjusted HRs for OS increased to 2.95, 3.64 and 3.82 (p for trend being 0.015), respectively.
Conclusions
Integration of expression rate and cell counts of stromal PD1+ TILs had a significant prognostic effect in terms of relapse and overall survival. Further studies are warranted to provide reference for immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Beijing Hospitals Authority.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract